Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-021-83229-6 http://scihub22266oqcxt.onion/10.1038/s41598-021-83229-6 33574416!7878891!33574416     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Rep 2021 ; 11 (1): 3640 Nephropedia Template TP {{tp|p=33574416|t=2021. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2 |pdf=|usr=}}{{33574416}} gab.com Text Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2 JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=33574416 #FOAvip An efficient treatment against a COVID-19 disease, caused by the novel coronavirus SARS-CoV-2 (CoV2), remains a challenge. The papain-like protease (PL(pro)) from the human coronavirus is a protease that plays a critical role in virus replication. Moreover, CoV2 uses this enzyme to modulate the host's immune system to its own benefit. Therefore, it represents a highly promising target for the development of antiviral drugs. We used Approximate Bayesian Computation tools, molecular modelling and enzyme activity studies to identify highly active inhibitors of the PL(pro). We discovered organoselenium compounds, ebselen and its structural analogues, as a novel approach for inhibiting the activity of PL(pro)CoV2. Furthermore, we identified, for the first time, inhibitors of PL(pro)CoV2 showing potency in the nanomolar range. Moreover, we found a difference between PL(pro) from SARS and CoV2 that can be correlated with the diverse dynamics of their replication, and, putatively to disease progression. Twit Text FOAVip Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2 ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=33574416 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33574416 #FOAvip English Wikipedia <ref>{{Cite pmid|33574416}}</ref> Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2 #MMPMID33574416 Weglarz-Tomczak E; Tomczak JM; Talma M; Burda-Grabowska M; Giurg M; Brul S Sci Rep 2021[Feb]; 11 (1): 3640 PMID33574416show ga An efficient treatment against a COVID-19 disease, caused by the novel coronavirus SARS-CoV-2 (CoV2), remains a challenge. The papain-like protease (PL(pro)) from the human coronavirus is a protease that plays a critical role in virus replication. Moreover, CoV2 uses this enzyme to modulate the host's immune system to its own benefit. Therefore, it represents a highly promising target for the development of antiviral drugs. We used Approximate Bayesian Computation tools, molecular modelling and enzyme activity studies to identify highly active inhibitors of the PL(pro). We discovered organoselenium compounds, ebselen and its structural analogues, as a novel approach for inhibiting the activity of PL(pro)CoV2. Furthermore, we identified, for the first time, inhibitors of PL(pro)CoV2 showing potency in the nanomolar range. Moreover, we found a difference between PL(pro) from SARS and CoV2 that can be correlated with the diverse dynamics of their replication, and, putatively to disease progression. |*Molecular Docking Simulation[MESH] |Antiviral Agents/chemistry/*pharmacology[MESH] |Azoles/chemistry/*pharmacology[MESH] |Binding Sites[MESH] |Coronavirus Papain-Like Proteases/*antagonists & inhibitors/chemistry/metabolism[MESH] |Isoindoles[MESH] |Organoselenium Compounds/chemistry/*pharmacology[MESH] |Protease Inhibitors/chemistry/*pharmacology[MESH]Identification of ebselen and its analogues as potent covalent inhibit(epmc).pdf DeepDyve Pubget Overpricing